Skip to main content
Premium Trial:

Request an Annual Quote

Genomenon Raises $2.5M in Equity Financing Round

This article has been updated to reflect the total amount of genomic variants the Mastermind engine is able to index. 

NEW YORK (GenomeWeb) – Genomenon announced today that it has raised $2.5 million in an equity financing round, in a move to expand its reach with clinical diagnostic labs, and biotech and pharmaceutical firms.

Investors in the equity round included IrishAngels and H.W. Kaufman Group, in addition to Genomenon's earlier investors. The firm said it planned to raise $2 million, and the round was oversubscribed because of strong investor interest.

The Ann Arbor, Michigan-based company said it will spend the funds on new marketing efforts and on increasing the size of its sales team to handle growing customer demand.

Genomenon's Mastermind Genomic Search Engine allows clinicians to index nearly 5 million genomic variants from data found in scientific publications. The firm believes the tool will help doctors provide faster and better treatment decisions for patients with rare diseases and cancer.

"We've seen strong demand from clinical labs desiring to accelerate their genomic interpretation process, and from pharmaceutical companies who want to license the data," Genomenon CEO Mike Klein said in a statement. "Mastermind is eliminating the variant interpretation bottleneck for clinical labs and providing pharma and biotech companies with a comprehensive genomic landscape in order to identify genomic biomarkers for drug discovery and clinical trials."

In October 2018, Genomenon partnered with GenomOncology to incorporate the Mastermind search engine into GenomOncology's molecular tumor board software.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.